Helicobacter pylori Treatment Strategies in Singapore

Tiing Leong Ang, Daphne Ang, Tiing Leong Ang, Daphne Ang

Abstract

The management of Helicobacter pylori infection in Singapore remains a clinical challenge. Similar to other regions, there has been an increase in antibiotic resistance rates through the years. Nonetheless, over the past two decades, clarithromycin-based triple therapy has continued to be used as the first line treatment option, with an eradication rate exceeding 90%, although the accepted treatment duration must now be lengthened from 1 to 2 weeks to maintain efficacy. Concomitant and sequential therapies did not demonstrate superiority over standard triple therapy. Current empiric second line treatment utilizes either bismuth-based quadruple therapy or levofloxacin-based triple therapy, but outcomes remain less than ideal. Identifying options to further improve treatment success rates is challenging. Strategies being considered include the use of potent acid suppressants, such as vonoprazan, and H. pylori culture and antibiotic susceptibility testing-guided therapy.

Keywords: Antibiotic resistance; Eradication; Helicobacter pylori.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

References

    1. Singapore Department of Statistics, author. Population Trends 2018 [Internet] Department of Statistics, Ministry of Trade & Industry, Republic of Singapore; c2018. [cited 2019 Sep 8]. Available from: .
    1. Singapore Department of Statistics, author. Census of population 2010 [Internet] Department of Statistics, Ministry of Trade & Industry, Republic of Singapore; c2011. [cited 2019 Sep 8]. Available from: .
    1. Fock KM. Helicobacter pylori infection: current status in Singapore. Ann Acad Med Singapore. 1997;26:637–641.
    1. Ang TL, Fock KM, Dhamodaran S, Teo EK, Tan J. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol. 2005;20:1603–1609. doi: 10.1111/j.1440-1746.2005.03898.x.
    1. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600. doi: 10.1111/j.1440-1746.2009.05982.x.
    1. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–1386. doi: 10.1111/jgh.12607.
    1. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367. doi: 10.1136/gutjnl-2015-309252.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288.
    1. Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37–56. doi: 10.1111/jgh.13911.
    1. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51–69. doi: 10.1053/j.gastro.2016.04.006.
    1. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44–53. doi: 10.1053/j.gastro.2019.04.011.
    1. Zhao B, Zhao J, Cheng WF, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol. 2014;48:241–247. doi: 10.1097/MCG.0b013e31829f2e25.
    1. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–1418. doi: 10.1111/j.1365-2036.2005.02444.x.
    1. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;(2):CD004062. doi: 10.1002/14651858.CD004062.pub2.
    1. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–1124. doi: 10.1053/j.gastro.2016.01.028.
    1. Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2011;13:540–546. doi: 10.1007/s11894-011-0226-4.
    1. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757–766. doi: 10.1046/j.1365-2036.2003.01766.x.
    1. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002;16:1149–1156. doi: 10.1046/j.1365-2036.2002.01270.x.
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi: 10.1136/gut.2009.192757.
    1. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357. doi: 10.1111/j.1365-2036.2007.03386.x.
    1. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337. doi: 10.1002/14651858.CD008337.pub2.
    1. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121–128. doi: 10.1053/j.gastro.2013.03.050.
    1. Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment Pharmacol Ther. 2000;14:225–231. doi: 10.1046/j.1365-2036.2000.00691.x.
    1. Wong BC, Xiao SD, Hu FL, et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. Aliment Pharmacol Ther. 2000;14:217–224. doi: 10.1046/j.1365-2036.2000.00689.x.
    1. Ang TL, Wang L, Ang D, Chiam P, Fock KM, Teo EK. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis. 2013;14:100–104. doi: 10.1111/1751-2980.12024.
    1. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069–3079. doi: 10.1038/ajg.2009.555.
    1. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109–118. doi: 10.1111/j.1523-5378.2009.00671.x.
    1. Ang TL, Fock KM, Song M, et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol. 2015;30:1134–1139. doi: 10.1111/jgh.12892.
    1. Ang TL, Fock KM, Ang D, Kwek AB, Teo EK, Dhamodaran S. The changing profile of Helicobacter pylori antibiotic resistance in Singapore: a 15-year study. Helicobacter. 2016;21:261–265. doi: 10.1111/hel.12291.
    1. Chew CA, Lye TF, Ang D, Ang TL. The diagnosis and management of H. pylori infection in Singapore. Singapore Med J. 2017;58:234–240. doi: 10.11622/smedj.2017037.
    1. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan YL. Efficacy of quadruple therapy for Helicobacter pylori eradication after failure of proton pump inhibitor based triple therapy in Singapore. Chin J Dig Dis. 2003;4:35–39. doi: 10.1046/j.1443-9573.2003.00102.x.
    1. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278. doi: 10.1111/j.1523-5378.2007.00518.x.
    1. Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014;1:19. doi: 10.3389/fmolb.2014.00019.
    1. Vécsei A, Innerhofer A, Binder C, et al. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin Gastroenterol Hepatol. 2010;8:309–312. doi: 10.1016/j.cgh.2009.12.002.
    1. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol. 1999;94:725–729. doi: 10.1111/j.1572-0241.1999.00943.x.
    1. Kwon YH, Kim N, Lee JY, et al. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scand J Gastroenterol. 2016;51:270–276. doi: 10.3109/00365521.2015.1095352.
    1. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878. doi: 10.1136/gutjnl-2015-311019.
    1. Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter. 2019;24:e12565. doi: 10.1111/hel.12565.
    1. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446. doi: 10.1136/gutjnl-2015-311304.
    1. Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23:e12495. doi: 10.1111/hel.12495.
    1. Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17:29. doi: 10.1186/s12941-018-0281-x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe